Where we offer three class 100,000 cGMP Suites for Pre-Clinical and Clinical Manufacturing and 23 Reactors with a total of 20,000 Gallons of API Manufacturing Capacity.
Read all of our Blog posts on API Manufacturing »
At PCI Synthesis, part of SEQENS CDMO, we understand the challenges in cGMP API manufacturing when you’re moving your project from the lab to the plant.
By the time your API synthesis is ready to be introduced into cGMP manufacturing a significant investment in both time and money has been expended. Whether you’re looking to produce critical, clinical phase I-III trial material, material for commercial launch, or on-going API supply everything we do is geared toward making this final step as smooth and successful as possible. The jump to cGMP manufacturing is never simple or easy. Producing complex molecules within specification the first time in cGMP is fraught with potential peril at every turn.
That’s why we’ve built a seamless development solution that enables you to begin your active pharmaceutical ingredient development in our Devens R&D lab and then migrate it directly into our cGMP Newburyport API plant, where we offer up to 20,000 gallons of manufacturing capacity. Because of our closely aligned R&D API synthesis and scale-up capabilities, you can feel confident in knowing that we’ll be with you all the way, from discovery to commercialization.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling